Production process analysis: a review of the device history record confirmed that the device was manufactured and tested according to relevant procedures, and shipped according to manufacturer's specifications.User (surgeon and patient) information analysis: on (b)(6) 2024, apifix was notified that patient (b)(6) will be undergoing implant removal at norton children's for possible infection.It was further reported that 1g of vancomycin was used during the index surgery.On (b)(6) 2024 apifix was notified that hardware removal was performed on (b)(6) 2024 and there were signs of infection noted during removal surgery.Culture taken, awaiting results.Device is expected to be returned to manufacturer for evaluation.Risk assessment late-onset infection is a known risk which was assessed and recorded by the product risk assessment.This complaint does not change the occurrences rate.The event of late infection is addressed in the ifu (dms-4472 rev g) as a warning and as potential risks associated with the mid-c system and spinal surgery generally.The explanted device is expected to be returned to the manufacturer and will be evaluated.Following the evaluation, if new pertinent information comes to light, then a supplemental medwatch report will be submitted.
|